The Department of Biotechnology (DBT), Government of India, and
Piramal Life Sciences have begun phase II of their drug discovery
public private partnership to find new drugs from 14,000 bioactive
cultures discovered in a nationwide search for new drugs from
biodiverse habitats across the country in collaboration with nine
national institutes. During the phase I of the program, which is
jointly funded by the DBT and and Piramal Life Sciences, a total of
245,000 different microbes were collected and characterized at the
national centers. Extracts from these microbes were screened for
biological activities across four different therapeutic areas -
cancer, diabetes, inflammation and infectious diseases. Based on the
results of these studies, the team has identified greater than
14,000 cultures that showed potent activities in the above disease
conditions: 5,000 extracts for anti-infective, 500 extracts for
anti-cancer, 6,000 for anti-diabetes and 2,900 extracts with
anti-inflammatory properties. All these cultures are in the process
of classification and storage in a national repository created by
the DBT at the National Centre for Cell Science.
Innovative
research at KIIT University
Bhubaneswar-based KIIT-technology business incubator at KIIT
University is working on many innovative concepts supported by the
Department of Science & Technology, Govt of India. The team
headed by Dr Mrutyunajy Suar includes Mr Vikalp Viswakarma and Mr
Niladri Bhusan Patia. The team is trying to develop the safest
vaccine to provide protection against several diarrheal diseases
caused by bacterial pathogens Salmonella, Shigella, E. coli and
Vibrio cholera. This is being tested in mice and has shown promising
results so far. Dr Suar and Mr Satyapriya Jena have also developed a
multiplex PCR protocol to identify the causative agents of diseases
within two hours.
Focusing on the rural mass, such tests are being developed at very
low price.Also, Ms Regalin Rout and Prof Peter Luthy at KIIT
identified and isolated unique bacterial strain from the
agricultural fields that is highly active against the larvae of
Culex, Aedes and Anopheles.
Conference held on managing BT crops
At the round table conference organized by The Energy and Resources
Institute (TERI) at New Delhi, the experts from academia and
industry discussed various burning issues on the management of
biotech crops. TERI organized the conference titled “Managing
Biotech Crops� (July 4-5, 2011) in New Delhi. The conference
witnessed detailed discussion between policy makers, experts from
research institutes and industry representatives. There was an
overall consensus among experts on the improvement of effective
science communication, dissemination of knowledge on biotech crops,
and the re-look on the regulatory mechanisms. The two-day conference
witnessed technical sessions on sustainability of food production,
genetic improvement of crop plants, choices of usage, global
acceptability and lack of harmonization of regulatory laws, good
agricultural practices and developing risk assessment &
management procedures. The concluding session was chaired by Dr M K
Bhan, secretary, Department of Biotechnology.
Indo-US
partner in biotech research
The Stanford India Biodesign program has resulted in 20 patents
being filed and several proto-types of affordable bio-medical
devices and technologies developed that are at various
pre-commercialization stages. Minister of State for Science and
Technology and Earth Sciences Ashwani Kumar, at INDO-US Science and
Technology Innovation Expo in New Delhi on July 19, said the two
countries will take this forward. India and the US will also partner
to address challenges of wheat genome sequencing; human
genetic-genome analysis; stem cell research; nano biotechnology;
plant breeding technologies and food security; micro-electronics and
material science technology; nano science and supercomputing.
Aeras, CNBG MoU for TB vaccines
Aeras and the China National Biotech Group (CNBG) have signed a
memorandum of understanding for the organizations to jointly develop
tuberculosis (TB) vaccines in China and other parts of the world.
The partnership is intended to leverage both organizations'
capabilities to support the development of TB vaccines. The scope of
potential activities will cover the full spectrum of product
development, including pre-clinical development, process development
and manufacturing, and clinical development in TB and potentially
other disease areas. Details of the specific activities and areas of
focus of the collaboration will be set forth in a future definitive
agreement.